Many people with constipation are confused about the cause of their condition and its appropriate treatment with laxatives. Results of a new large-scale global survey, announced today, show that many people wrongly fear that laxatives are addictive and that their use for long periods of time actually causes constipation.1,2
Combined data analysis from two trials demonstrated that treatment success is associated with mucosal healing in patients with moderately active ulcerative colitis who received either 2.4 or 4.8 grams of mesalamine per day. By 6 weeks, 67% of patients achieved both treatment success and mucosal healing, while only 5% achieved treatment success without demonstrating mucosal healing. The results were presented by University of Chicago researcher David T. Rubin, MD, at the annual scientific meeting of the American College of Gastroenterology (ACG).
The gastrointestinal medicine Zelnorm? (tegaserod maleate) has demonstrated potential benefits in helping patients with the multiple symptoms of a common digestive disorder called dysmotility-type dyspepsia[1], according to new Phase III data presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting.
Abbott announced results from a study showing HUMIRA? (adalimumab) induced significantly higher rates of clinical remission compared to placebo in patients with moderately to severely active Crohn’s disease who lost response to, or were intolerant to, infliximab therapy. The data is being presented simultaneously at the American College of Gastroenterology (ACG) annual meeting in Las Vegas and the United European Gastroenterology Week (UEGW) in Berlin.
Speaking at a Ferring-sponsored symposium on the occasion of the 14th United European Gastroenterology Week (UEGW) congress, Christoph Gasche, Associate Professor of Medicine, Medical University of Vienna, Austria presented the findings of an in-vitro study which for the first time demonstrates a mode of action by which mesalazine may reduce the risk of colorectal cancer in Inflammatory Bowel Disease (IBD) patients.
In another important milestone, Glivec? (imatinib) has received US regulatory approval to help patients with five distinct and potentially life-threatening disorders, representing the first time that a regulatory authority has ever simultaneously approved one targeted medicine for so many disorders. With today’s decision, and in only five years, Glivec has now been approved in the US for seven diseases, including two solid tumors and five blood disorders with molecular targets known to be inhibited by the drug.
Eli Lilly and Company has launched a major clinical trial evaluating ALIMTA (pemetrexed for injection) in extensive-stage small cell lung cancer (SCLC), a devastating and rapidly spreading form of lung cancer. This international trial, expected to be the largest ever to be conducted in SCLC(1), will assess the potential clinical benefit of pemetrexed in combination with carboplatin, a commonly-used chemotherapeutic agent, in direct comparison to the current leading treatment option of etoposide in combination with carboplatin.
A child?s susceptibility to autism is increased with a single gene mutation according to research conducted by, a Vanderbilt-led research team. This discovery has far-reaching implications because this gene, a variant form of a gene called MET, is not just specifically a brain gene but rather a gene which has its effect on multiple systems in the body such as immune function and gut repair.
Agennix today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s oral formulation of Talactoferrin Alfa (talactoferrin or TLF) for the treatment of renal cell carcinoma (RCC). Oral TLF is currently in Phase II clinical development for RCC. Results from a multi-center Phase 2 RCC trial that included six leading U.S. cancer centers were presented at the 2006 Annual meeting of the American Society of Clinical Oncology (ASCO).
The millions of Americans afflicted with Type 1 and 2 Diabetes face many potential complications,including: heart and kidney disease; nerve damage and stroke; foot and skin problems; and gastrointestinal disorders and hypoglycemia.